You may ask, where do cyclodextrin experts learn new tricks?
Of course, from other experts!
That is why we were extremely, grateful when Carmen Popescu from Roquette offered to give us a 2-day in person training. Even more so as Mohammad Qadir joined too.
So we gathered a small team of students and colleagues and are now bathing in cyclodextrin formulations.
Who wants to join the next session? 🙂
Richárd Tóth – Andrea Trifoglio – Janka Juhász
In this study – differing from the GENEGUT concept – our CSO, Milo Malanga PhD, designed cyclodextrin polymers that can form nanoplexes with various oligonucleotides due to their cationic nature. The we compared them with a standard polymer in the field: polyethylenimine.
QABCDPS exhibited lower toxicity compared to PEI, effectively binding both siRNA and mRNA and delivering them into vesicles in the cytoplasm, but showing different internalization patterns.
Polyplexes formed with PEI showed stronger biological effect than those with QABCDPS, which can be attributed to the strength of interactions facilitated by the polymers.
We hope to continue the collaboration with University of Debrecen – especially Ágnes Rusznyák and Ferenc Fenyvesi and design more efficient shuttles for the next round.
Our long-time friends and partners at Cyclarity Unveil First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol
Daniel Clemens recently presented the first data from Cyclarity Therapeutics‘ ongoing Phase I trial with UDP-003
Key highligths:
1. Safe excretion of 7KC (7-keto-cholesterol), a core driver of plaque associated with heart disease, stroke, inflammation, and age-related diseases, in humans suggests medicine could move beyond slowing heart disease to disease-modifying plaque reversal
2. First candidate from Cyclarity’s AI Platform reinforces promise of next-generation cyclodextrins to reverse disease and protect against future accumulation of harmful molecules and aging pathologies
Cyclarity’s UDP-003 binds directly to 7KC, the root cause of plaque buildup, then facilitates urinary excretion of it. Much like removing rust from metal, this approach directly targets a key source of damage within plaque with the goal of reversing and preventing atherosclerosis, a primary underlying cause of cardiovascular disease, and does so locally within the plaque to reduce risks of unintended systemic effects.
Plaque reversal is significant because research suggests that even a 1% reduction in coronary plaque burden has been associated with up to 25% lower risk of major cardiovascular events, such as heart attack or stroke.
In parallel, they are preparing for the launch of our Phase 2 trial, expected to kick off in early 2027.
Cyclarity Therapeutics is a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease.
Read the full story here: Cyclarity Unveils First-Ever Clinical Data Demonstrating
I am deeply honored to be invited by PhD Circle (Gjylije Hoti & Visar Vela) to talk about The CarboHyde story
My title is “From Vision to Impact: The Cyclodextrin Revolution at CarboHyde.”
Join us online to discover how innovative applications of cyclodextrins are driving breakthroughs across industries, and how scientific vision can be transformed into real-world impact through entrepreneurship and cutting-edge research.
🗓️ 21 May, 2026
🕖 19:00 CET
📍 Online
🔗https://lnkd.in/da-zSjXH
Don’t miss this opportunity to be a part of the conversation shaping tomorrow’s innovations.
Oops, we did it again.
This time with CNR: Nino Mazzaglia, Giuseppe Pappalardo and may others and of course our dear Milo Malanga.
Together we explored the role, chemistry and biology of defensins, of course with the help of cyclodextrins, particularly succinylated-BCD polymer.
Defensins are a large and ancient family of host–defence peptides present across vertebrates, invertebrates, and plants, where they play a crucial role in innate immunity.
What can we bring out of cyclodextrin polymers at CarboHyde?
Whatever you want, apparently 🙂
Our long-term collaboration with Salvo Sortino‘s team and Szabolcs Béni just yielded another great paper with Milo Malanga.
Here, we made a photoresponsive β-cyclodextrin branched polymer, where excitation of the Poly-βCD1 with visible blue light results in the generation of nitric oxide.
The negligible cytotoxic action of DOX, used well below the therapeutic doses, alone or in combination with the polymer in the dark, is enhanced in both cell lines under light irradiation exclusively when the drug is combined with Poly-βCD1 as a result of the combined action of NO.
Whatever you want, apparently 🙂
Our long-term collaboration with Salvo Sortino‘s team and Szabolcs Béni just yielded another great paper with Milo Malanga.
Here, we made a photoresponsive β-cyclodextrin branched polymer, where excitation of the Poly-βCD1 with visible blue light results in the generation of nitric oxide.
The negligible cytotoxic action of DOX, used well below the therapeutic doses, alone or in combination with the polymer in the dark, is enhanced in both cell lines under light irradiation exclusively when the drug is combined with Poly-βCD1 as a result of the combined action of NO.
Using CDs for wound healing has been in the spotlight for a long time, many applications and promising prototypes were developed, yet none reached the market.
This may change with the innovation of Jun Li at National University of Singapore who made a smart multifunctional ROS-responsive supramolecular hydrogel.
The polymer is dynamically crosslinked by inclusion complexes of β-cyclodextrin (βCD) and ferrocene (Fc).
This hydrogel facilitates the on-demand release of interleukin-4 (IL-4) while exhibiting intrinsic antibacterial properties.
The system subsequently reprograms macrophages from the proinflammatory M1 phenotype to the anti‒inflammatory M2 phenotype, thereby addressing immune dysregulation in diabetic wounds.
The composition significantly enhanced wound closure, collagen density, and angiogenesis while reducing proinflammatory cytokines (IL-6 and TNF-α) and increasing anti‒inflammatory cytokine IL-10 levels.
Smart multifunctional ROS-responsive supramolecular hydrogel for simultaneously regulating oxidative stress, immune dysregulation, and bacterial infection in diabetic wound healing – ScienceDirect
Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months.
Alternative therapeutic strategies—such as targeting the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway with MEK inhibitors like trametinib and selumetinib—are being explored.
However, their clinical success is currently hindered by inadequate delivery across the blood–brain barrier and dose-limiting toxicity.
In this work, Noemi Bognanni, Graziella Vecchio and colleagues investigate two cationic CyD polymers as potential nanocarriers for GB therapy based on trametinib and selumetinib.
Their multivalent architecture and positive charge can facilitate both the encapsulation of drugs and membrane interactions.
Now our global player in Centrifugal Partition Chromatography (CPC), RotaChrom Technologies published about Scalable enantioseparation of rac-voriconazole.
Features?
– Batch CPC sets the baseline, intensified to cyclic continuous stacked-injection CPC.
– MDM CPC mode enables continuous injection and dual-outlet product collection.
– MDM CPC intensification delivers an overall ≈25× productivity gain vs resolution.
– Continuous CPC reduces solvent and selector use via repeated phase recycling.
And the best part?
The cyclodextrin, of course. To improve process economics, sulfobutyl ether-β-cyclodextrin (SBE-β-CD) was replaced with lower-cost randomly methylated β-cyclodextrin (RM-β-CD) without compromising the partitioning and selectivity required for MDM operation.
Continuous MDM CPC afforded (2R,3S)-voriconazole at ≥99.8% optical purity and 99.9% enantiomeric excess (ee), with 81% isolated yield
Congrats to Anita Kiss, Dóra Rutterschmid, Szabolcs Muráth!
